Jan 2 |
Regulus Therapeutics Announces Completion of Enrollment in Third Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)
|
Dec 27 |
Regulus Therapeutics files for $150M mixed shelf
|
Nov 22 |
Regulus Therapeutics to Present at the 6th Annual Evercore ISI HealthCONx Conference
|
Nov 10 |
Regulus Therapeutics GAAP EPS of -$0.40
|
Nov 9 |
Regulus Therapeutics Reports Third Quarter 2023 Financial Results and Recent Updates
|
Nov 2 |
Regulus Therapeutics Announces First Patient Dosed in Third Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
|
Oct 19 |
Regulus Therapeutics Advances to Cohort 3 of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
|